Chronic Obstructive Pulmonary Disease (COPD) Market Size And Forecast 2024-2032

Veröffentlicht 2024-09-04 08:43:10

394

Chronic Obstructive Pulmonary Disease (COPD) Market Analysis

The Global Chronic Obstructive Pulmonary Disease (COPD) Market was valued at US$ 13.25 billion in 2023. It is estimated that the market will be worth US$ 17.22 billion by 2032, with a projected compound annual growth rate (CAGR) of 2.96% from 2024 to 2032. Factors contributing to this growth include, increased use of cigarettes among young people, greater awareness of the advantages of using generic drugs, globalization, improved literacy rates, healthcare reforms, and the healthcare spending policies of third-world countries.

COPD Market Overview

Chronic Obstructive Pulmonary Disease (COPD) is a long-term, progressive lung condition that obstructs airflow, making it difficult to breathe. It primarily includes two diseases: emphysema, which damages the air sacs (alveoli) in the lungs, and chronic bronchitis, characterized by inflammation of the airways and excessive mucus production. The main cause of COPD is prolonged exposure to irritants like cigarette smoke, though long-term exposure to air pollution, chemical fumes, and dust can also contribute.

Request a free sample copy of the report: https://www.renub.com/chronic-obstructive-pulmonary-disease-market-p.php

Symptoms of COPD include persistent cough, shortness of breath, wheezing, and frequent respiratory infections. These symptoms gradually worsen over time, severely impacting daily activities. COPD is a leading cause of disability and death worldwide, particularly among older adults. Although there is no cure, treatments such as medication, oxygen therapy, and lifestyle changes can help manage symptoms and improve quality of life for those affected. Early diagnosis and management are crucial for slowing disease progression.

key growth factors driving the Chronic Obstructive Pulmonary Disease (COPD) industry:

Aging Population and Increased Prevalence of COPD

The global aging population is a significant driver in the COPD industry. As people age, their risk of developing COPD increases due to longer exposure to risk factors like smoking and air pollution. With the number of elderly individuals rising, especially in developed regions like North America and Europe, the demand for COPD diagnostics, treatments, and management solutions is also increasing. Additionally, better awareness and more frequent diagnosis have led to a higher reported prevalence of COPD, expanding the market for medications, pulmonary rehabilitation, and other therapeutic interventions. The growing need for long-term care further boosts this industry’s growth.

Technological Advancements in COPD Treatment and Management

Advancements in medical technology, particularly in the development of inhalation devices, have significantly enhanced the treatment and management of COPD. Innovations like smart inhalers, which track usage and provide personalized feedback, improve medication adherence and patient outcomes. Additionally, the development of combination therapies that deliver multiple drugs through a single inhaler simplifies treatment regimens, enhancing patient compliance. Telemedicine and remote monitoring solutions also play a crucial role in chronic disease management, allowing healthcare providers to track patient progress and adjust treatment plans in real-time. These technological innovations are driving growth by making COPD care more effective and accessible.

Government Initiatives and Healthcare Expenditure

Rising government initiatives focused on managing chronic diseases are propelling growth in the COPD industry. Public health campaigns, smoking cessation programs, and regulations to reduce air pollution aim to lower COPD incidence rates. Additionally, increased healthcare spending in both developed and developing regions is improving access to diagnostics and treatment, allowing more patients to receive timely care. Governments and healthcare organizations are investing in awareness programs and early detection initiatives, which lead to early intervention and better disease management. These efforts, along with subsidies for COPD medications, are enhancing market growth by addressing both prevention and treatment aspects of the disease.

North America Chronic Obstructive Pulmonary Disease Market

The North America Chronic Obstructive Pulmonary Disease (COPD) market is witnessing steady growth due to several key factors. The region has a significant aging population, particularly in the U.S. and Canada, where the prevalence of COPD is high. The rising incidence of smoking, coupled with exposure to environmental pollutants, continues to drive the demand for effective COPD management solutions. Additionally, the market benefits from well-established healthcare infrastructure and increased access to advanced treatment options, including combination therapies, smart inhalers, and telehealth services.

Government initiatives and public awareness programs focused on early diagnosis and smoking cessation are further fueling market growth. The presence of major pharmaceutical companies, continuous R&D activities, and growing adoption of innovative technologies like digital health solutions are also key contributors. As healthcare expenditure rises and awareness of chronic respiratory diseases improves, the North America COPD market is expected to expand in the coming years.

Chronic Obstructive Pulmonary Disease Market Company Overview

The Global Chronic Obstructive Pulmonary Disease (COPD) Market is steered by industry leaders who have demonstrated their commitment and expertise. These leaders, including AstraZeneca, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Astellas Pharma Inc., Abbott Laboratories, Boehringer Ingelheim International GmbH, and Almirall, play a crucial role in shaping the market's future.

Chronic Obstructive Pulmonary Disease (COPD) Market News

In April 2024, A report on the results of the Phase 2a COURSE trial for TEZSPIRE (tezepelumab-ekko) in patients with chronic obstructive pulmonary disease was issued by Amgen. Tezelumab was found to statistically lower the annualized rate of moderate-to-severe COPD exacerbations by 17%.

In March 2024, in head-to-head research using a human tissue model of chronic obstructive pulmonary disease, ASLAN Pharmaceuticals Ltd. reported new, encouraging translational evidence that supports eblasakimab's potential as a biologic therapy for COPD. The study pitted eblasakimab against dupilumab.

In February 2024, Regeneron Pharmaceuticals, Inc. and Sanofi declared that the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in a sixth potential indication as an add-on maintenance treatment in specific adult patients with uncontrolled chronic obstructive pulmonary disease had been accepted for Priority Review by the US FDA.

In September 2024, Verona Pharma plc said that the company's New Drug Application (NDA) for ensifentrine, which seeks clearance for the maintenance treatment of patients with chronic obstructive pulmonary disease, has been authorized by the US Food and Drug Administration (FDA).

Related Report:

Oncology Precision Medicine Market: https://www.renub.com/oncology-precision-medicine-market-p.php

Personalized Medicine Market: https://www.renub.com/personalized-medicine-diagnostics-flow-cytometry-sepsis-immunos-routine-coagulation-psychiatric-disorders-tumor-markers-molecular-blood-typing-and-other-testing-market-and-forecast-454-p.php

Precision Medicine Market: https://www.renub.com/precision-medicine-market-p.php

Types – Market breakup in 2 viewpoints:

1. Chronic Bronchitis

2. Emphysema

Treatment Types – Market breakup in 4 viewpoints:

1. Drugs

2. Oxygen Therapy

3. Surgery

4. Others

Distribution Channel– Market breakup in 3 viewpoints:

1. Hospital Pharmacies

2. Retail Pharmacies

3. Online Pharmacies

Country – Market breakup in 25 viewpoints:

North America

o United States

o Canada

Europe

o France

o Germany

o Italy

o Spain

o United Kingdom

o Belgium

o the Netherlands

o Turkey

Asia Pacific

o China

o Japan

o India

o Australia

o South Korea

o Thailand

o Malaysia

o Indonesia

o New Zealand

Latin America

o Brazil

o Mexico

o Argentina

Middle East & Africa

o South Africa

o Saudi Arabia

o United Arab Emirates

All the Key players have been covered from 4 Viewpoints:

1. Overviews

2. Recent Developments & Strategies

3. Product Portfolio & Product Launch in Last 1 Year

4. Revenue

Company Analysis:

1. AstraZeneca

2. Pfizer, Inc.

3. GlaxoSmithKline plc.

4. Novartis AG

5. Astellas Pharma Inc.

6. Abbott Laboratories

7. Boehringer Ingelheim International GmbH

8. Almirall

About the Company:

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.